Gene Therapy Pioneer Roger Hajjar, MD, Elected to Longeveron® Board of Directors

Core Insights - Longeveron Inc. has elected Dr. Roger Hajjar to its Board of Directors, enhancing its leadership in the field of gene and cell therapy [1][7] - Dr. Hajjar is recognized for his contributions to cardiac gene therapy and has initiated multiple clinical trials for cardiovascular diseases [2][4] - The company is advancing its lead product, Lomecel-B™, which has shown potential in treating conditions like hypoplastic left heart syndrome (HLHS) and Alzheimer's disease [3][5] Company Overview - Longeveron is a clinical stage biotechnology company focused on developing regenerative medicines to meet unmet medical needs [5] - The lead investigational product, Lomecel-B™, is an allogeneic medicinal signaling cell therapy derived from the bone marrow of young, healthy adult donors [5] - Lomecel-B™ has received significant FDA designations, including Orphan Drug, Fast Track, and Rare Pediatric Disease designations for its HLHS program [5] Leadership and Strategic Direction - Dr. Hajjar's appointment is part of a planned Board refreshment process aimed at incorporating experienced leaders to enhance the company's knowledge base [7] - The company aims to leverage Dr. Hajjar's expertise to advance its therapeutic development programs, particularly in gene and cell therapy [7]